STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-12-31

Summary

The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

• Phase: PHASE2

Details

• Lead Sponsor: Canadian Cancer Trials Group
• Collaborators: AstraZeneca; National Cancer Institute, Naples
• Treatments: durvalumab; lenvatinib; tremelimumab